Nektar Therapeutics (NASDAQ: NKTR) said Wednesday that patients treated with rezpegaldesleukin in atopic dermatitis showed improvements as early as Week 2 of treatment, a timeline the company linked to rezpegaldesleukin-associated molecular changes.

The disclosure, carried by MT Newswires on September 30, 2026, positions the onset of effect squarely within the window that matters most in competitive atopic dermatitis development: the first weeks of therapy, when patients and clinicians typically decide whether a treatment is working. The full text of the announcement sits behind MT Newswires' subscription paywall, and the details below reflect what Nektar has made publicly accessible.

What the company stated

Nektar reported two connected findings. First, improvements in atopic dermatitis were observed as early as Week 2. Second, those clinical improvements were associated with molecular changes the company attributes to rezpegaldesleukin. In other words, the company is not claiming only that patients felt better quickly; it is claiming a parallel biological signature that it ties to the drug's mechanism.

That framing matters for dermatology audiences. Early-onset data increasingly differentiates candidates in a field where biologics and small molecules are judged on speed to response as much as on endpoint magnitudes at Week 16. A Week 2 signal, if confirmed in full datasets and peer-reviewed publication, would place rezpegaldesleukin in the conversation on rapid onset alongside established and emerging atopic dermatitis therapies.

What remains unknown from the accessible announcement

The public portion of the release does not specify several items dermatologists will want before drawing conclusions:

• The study design — phase, randomization, blinding, and comparator arms, if any.
• The cohort — number of patients, baseline disease severity, and prior treatment exposure.
• The endpoint definitions — whether the Week 2 improvements were measured on EASI, validated itch scales, or other instruments.
• The magnitude of the effect sizes at Week 2 and how the response trajectory evolved beyond it.
• The dosing regimen administered.

Until Nektar publishes or presents the underlying data, the Week 2 claim should be read as a company statement rather than as independently verifiable trial results. As a matter of editorial practice, manufacturer-reported interim or exploratory findings warrant that distinction even when the signal is promising.

Why the timing claim carries weight

Rapid improvement is a clinically meaningful attribute in atopic dermatitis. Patients with moderate-to-severe disease often discontinue therapies they perceive as slow, and shared decision-making increasingly weighs time-to-response against route of administration and safety monitoring burden. If rezpegaldesleukin's molecular changes truly precede or coincide with symptomatic relief at Week 2, the compound's profile would address one of the persistent friction points in real-world adherence.

Molecularly anchored early response also gives investigators a pharmacodynamic marker to track, which can sharpen dose selection and patient stratification in later-stage work.

What to watch next

The next checkpoint will be fuller disclosure from Nektar — study design, cohort characteristics, quantified Week 2 endpoint results, and safety data — whether through a complete press release, a conference presentation, or a peer-reviewed manuscript. How the Week 2 improvement compares with the response kinetics of approved atopic dermatitis biologics will be the central question for clinicians evaluating the program.